


Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C

Aude Desnoyer^{1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100}, Dan Pospaj, Minh Patrick Lê, Anne Gervais, Alexandra Heurgué-Berlot, Achour Laradi, Stanislas Harent, Adriana Pinto, Dominique Salmon, Sophie Hillaire, Hélène Fontaine, David Zucman, Anne-Marie Simonpoli, Patrice Muret, Lucile Larrouy, Brigitte Bernard Chabert, Diane Descamps, Yazdan Yazdanpanah, Gilles Peytavin

See Editorial, pages 7–10



DOI: <http://dx.doi.org/10.1016/j.jhep.2016.02.044> |




Article Info

[Abstract](#) | [Full Text](#) | [Images](#) | [References](#) | [Supplemental Materials](#)








Background & Aims

Hepatitis C virus (HCV) infection is an independent risk factor for chronic kidney disease and leads to faster liver disease progression in patients requiring hemodialysis than in those with normal renal function. Little is known about the use of a sofosbuvir-containing regimen for infected patients on hemodialysis. We aimed to describe the pharmacokinetics, safety and efficacy of sofosbuvir in 2 dosing regimens and associated antiviral agents in

Graphical abstract



Article Tools

-  [PDF \(765 KB\)](#)
-  [Download Images\(.ppt\)](#)
About Images & Usage
-  [Email Article](#)
-  [Add to My Reading List](#)
-  [Export Citation](#)
-  [Create Citation Alert](#)
-  [Cited by in Scopus \(0\)](#)

-  [Request Permissions](#)
-  [Order Reprints](#)
(100 minimum order)


Related Articles

EASL Recommendations on Treatment of Hepatitis C 2015
Journal of Hepatology, Vol. 63, Issue 1
[Open Access](#)

EASL Clinical Practice Guidelines: Vascular diseases of the liver
Journal of Hepatology, Vol. 64, Issue 1

EASL Clinical Practice Guidelines:

HCV-infected patients requiring hemodialysis.



Methods

Multicenter, prospective and observational study of patients receiving sofosbuvir, 400 mg once daily ($n = 7$) or 3 times a week ($n = 5$), after hemodialysis with simeprevir, daclatasvir, ledipasvir or ribavirin was conducted. Drug plasma concentrations were determined by liquid chromatography-tandem mass spectrometry before and after a 4 h hemodialysis and 1.5 h after last drug intake at the end of hemodialysis.

Results

Plasma concentrations of sofosbuvir or its inactive metabolite sofosbuvir-007 did not accumulate with either regimen between hemodialysis sessions or throughout the treatment course. Sofosbuvir-007 extraction ratio (52%) was consistent with historical data. In one patient receiving the once daily regimen, sofosbuvir-007 half-life was slightly higher (38 h) than for patients with normal renal function receiving a full dose. Hemodialysis did not remove any other associated anti-HCV agents. Clinical and biological tolerance was good for all patients. Two relapses occurred with the 3 times a week regimen and none with the once daily.

Conclusions

A regimen including sofosbuvir, 400 mg once daily, could be proposed for HCV-infected patients requiring hemodialysis and should be associated with close clinical, biological, cardiovascular, and therapeutic drug monitoring.

Lay summary

Hepatitis C Virus (HCV) infection in hemodialysis patients is prevalent and aggressive. Effective anti-HCV treatment in these patients may stabilize their renal disease. However, sofosbuvir, the cornerstone of most anti-HCV-containing regimens, should not be administered to these patients until more data is available. In this pharmacokinetic study, sofosbuvir full dose (400 mg once daily) administered every day with another direct antiviral agent did not accumulate in hemodialysis patients and was safe and effective.

Abbreviations:

HCV (hepatitis C Virus), ESRD (end-stage renal disease), DAAs (direct-acting anti-HCV agents), SOF (sofosbuvir), LDV (ledipasvir), SOF-007TP (sofosbuvir uridine-triphosphate), SOF-007 (predominant sofosbuvir inactive metabolite GS-331007), QD (once daily), TIW (three times a week), DCV (daclatasvir), SMV (simeprevir), RBV (ribavirin), PegIFN (pegylated interferon), ALT (alanine aminotransferase), AST (aspartate aminotransferase), GGT (gamma-glutamyl transferase), pre-HD (blood samples collected just before 4-h hemodialysis), post-HD (blood samples collected just after 4-h hemodialysis), C1.5h (blood samples collected 1.5h after hemodialysis and dose intake), SVR (sustained virologic response)

Keywords:

Sofosbuvir, Hepatitis C Virus, Hemodialysis, Pharmacokinetics

To access this article, please choose from the options below

Log In

Email/Username:

Password:

Remember me

[Forgot password?](#)

Register

[Create a new account](#)

Purchase access to this article

- \$31.50 USD | [Online access for 24 hours](#)

Claim Access

If you are a current subscriber with Society Membership or an Account Number, [claim your access now](#).

Subscribe to this title

[Purchase a subscription](#) to gain access to this and all other articles in this journal.

Liver transplantation

Journal of Hepatology, Vol. 64, Issue 2

EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones

Journal of Hepatology, Vol. 65, Issue 1

EASL Recommendations on Treatment of Hepatitis C 2014

Journal of Hepatology, Vol. 61, Issue 2

[View All](#)

Institutional Access

[Visit ScienceDirect](#) to see if you have access via your institution.

© 2016 European Association for the Study of the Liver. Published by Elsevier Inc. All rights reserved.

[< Previous Article](#)

[July 2016](#) Volume 65, Issue 1, Pages 40–47

[Next Article >](#)

Copyright © 2016 [Elsevier](#) Inc. All rights reserved. | [Privacy Policy](#) | [Terms & Conditions](#) | [Use of Cookies](#) | [About Us](#) | [Help & Contact](#)

The content on this site is intended for health professionals.

Advertisements on this site do not constitute a guarantee or endorsement by the journal, Association, or publisher of the quality or value of such product or of the claims made for it by its manufacturer.